Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: J Neurooncol. 2017 Jan 23;132(1):181–188. doi: 10.1007/s11060-016-2357-9

Table 3C. Grade 3 and 4 toxicities attributed to aflibercept and temozolomide for Arm 3.

Adverse Event Aflibercept DL0 Aflibercept DL1 Temozolomide (DL0) Temozolomide (DL1)
Aspartate aminotransferase increase 1 1
Acute kidney injury 1
Creatinine increase 1
Anorexia 1 1
Fatigue 3 3
Headache 1 1
Hypertension 2
Vagus nerve disorder 1
Pain in extremity 1 1
Palmar-plantar erythrodysesthesia syndrome 2 2
Thromboembolic event 3
Leukopenia 2 3
Lymphopenia 1 4 1 7
Neutropenia 2 3
Thrombocytopenia 1 1
Investigations (other) 1